TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04836195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCLX-001
Description: To ensure maximal safety in this first-in-human trial, the starting dose level was chosen to be 20 mg daily on a 28-day cycle.
Study: NCT06441773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Rehabilitation
Description: An initial assessment is conducted upon admission to personalize the program. This includes:~Clinical examination Spirometry Maximum Inspiratory Pressure (PImax) measurement Multidimensional Dyspnea Profile questionnaire at end of TM6 Exercise Functional Testing Measurement of quadriceps strength and endurance Blood gases Educational interview and shared educational assessment London Chest Activity of Daily Living (LCADL) Tobacco and/or dietary consultation~The respiratory rehabilitation program, performed twice a week, includes:~Exercise training on an ergocycle and treadmill (30 minutes at ventilatory threshold for the ergocycle; 30 minutes at 60-80% walking speed for the treadmill; or dyspnea rated 4-6 on the Borg scale after endurance exercise) Quadriceps muscle strengthening Therapeutic education program Group gymnastics Smoking cessation assistance Socio-psychological and nutritional support
Study: NCT05064761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra new dilution
Description: Treatment to improve appearance of cellulite.
Study: NCT06566664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B Braun HNS 12 nerve stimulator
Description: Nerve stimulator that is traditionally used for nerve localization during block placements.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: B Braun HNS 12 nerve stimulator sham control
Description: Stimulator will be placed but will not be turned on.
Study: NCT05350202

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin
Study: NCT05592431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)
Description: ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Oscillatory Ventilation (SLE6000;SLE)
Description: ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
Study: NCT06125028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor
Description: \[68Ga\]Ga-PTF i.v. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]Fluorodeoxyglucose
Description: \[18F\]FDG i.v. injection.
Study: NCT05744128

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Zirconium 89Zr crefmirlimab berdoxam
Description: Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
Study: NCT05060471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
Study: NCT05361421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive targeting group
Description: Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
Study: NCT05781373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peep individualization
Description: Intraoperative Peep individualization in order to achieve the lowest driving pressure
Study: NCT06383403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: Round and orange film coated tablet of 80 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Round and orange film coated tablet of placebo
Study: NCT05508997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: respiratory parameters on mechanical ventilator (PEEP)
Description: The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: respiratory parameters on mechanical ventilator (PEEP)
Description: The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups.
Study: NCT04979520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
Study: NCT05936268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for injection
Description: 150 mg/1ml/bottle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5mg/table
Study: NCT05565482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work Chat: An Interactive Virtual Workday
Description: Study participants will receive Standard Transition Services plus Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
Study: NCT05825417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selexipag
Description: If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selexipag
Description: If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioMEMS pulmonary artery pressure monitor
Description: Implantation and remote monitoring established with patient initiated daily readings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioMEMS pulmonary artery pressure monitor
Description: Implantation and remote monitoring established with patient initiated daily readings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Confirm Rx
Description: Implantation and remote monitoring established with automated daily readings / downloads

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Confirm Rx
Description: Implantation and remote monitoring established with automated daily readings / downloads
Study: NCT06383884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
Study: NCT05450783

Intervention type: OTHER
Intervention: Biocollection
Description: serum
Study: NCT05785897

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation
Description: 'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible.~Eligible subjects will be pre-treated with DAPT consisting of aspirin (loading dose: 150-300 mg orally or 80-500 mg intravenously, maintenance dose: 75-100 mg daily orally) and a potent P2Y12 receptor inhibitor, either ticagrelor (loading dose: 180 mg orally, maintenance dose: 90 mg bd orally) or prasugrel (loading dose: 60 mg orally, maintenance dose: 10 mg od orally or 5 mg od orally if age \>75 years or weight \<60 kg) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.~Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation and final residual stenosis \<30% by visual estimation or 20% by QCA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation
Description: 'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible.~Eligible subjects will be pre-treated with DAPT consisting of aspirin (loading dose: 150-300 mg orally or 80-500 mg intravenously, maintenance dose: 75-100 mg daily orally) and a potent P2Y12 receptor inhibitor, either ticagrelor (loading dose: 180 mg orally, maintenance dose: 90 mg bd orally) or prasugrel (loading dose: 60 mg orally, maintenance dose: 10 mg od orally or 5 mg od orally if age \>75 years or weight \<60 kg) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.~Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation and final residual stenosis \<30% by visual estimation or 20% by QCA.
Study: NCT05974605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MM+HighC
Description: In this intervention, participants will be trained on a available mindfulness meditation app, followed by a working memory updating game, developed by Dr. Chandramallika Basak. This game requires high degree of attentional control (Unpredictable Bird Watch), also known as High-C. The app and the game are delivered through an Android tablet for this home-based training.
Study: NCT06466499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention group
Description: Is described in arm
Study: NCT04968587

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sustained Low-Efficiency Dialysis
Description: All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sustained Low-Efficiency Dialysis
Description: All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
Study: NCT06560840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
Study: NCT05214794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab
Description: nemolizumab will be administered subcutaneous injection
Study: NCT05550662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129Xenon
Description: There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.
Study: NCT05547048

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Decision aid for PrEP tailored for justice-involved women with opioid use disorder
Study: NCT06038851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Para-Sartorial Compartments (PACS) Block
Description: This intervention was selected because it has the potential to optimize analgesia by skin coverage of the upper third of the surgical incision. The intervention will be performed as follows:~* The intermediate femoral cutaneous nerve will be visualized at the supralateral level of the sartorius muscle, in a duplicature of the fascia lata.~* The needle will be inserted at the same puncture site as for the femoral triangle block, with a latero-medial orientation in the plane (intracanalar compartment).~* In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed in addition, below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Triangle Block (FTB)
Description: * The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~* The needle will be inserted with a latero-medial orientation in the plane.~* The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Triangle Block (FTB)
Description: * The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~* The needle will be inserted with a latero-medial orientation in the plane.~* The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration between popliteal artery and capsule of the knee (IPACK) block
Description: It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
Study: NCT05547048

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Athena strategy
Description: eHealth for integrated PrEP/medications for opioid use disorder + decision aid
Study: NCT06038851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration between popliteal artery and capsule of the knee (IPACK) block
Description: It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
Study: NCT06228742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral leg immobilization
Description: Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contralateral active leg
Description: One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
Study: NCT04699799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Present odors to participants while recording brain activity
Description: Present odors to participants while recording brain activity
Study: NCT06560281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Minder Therapy (MoMT)
Description: Motion Minder Therapy (MoMT) total duration is 1 hour a day, 5 days a week for 4 weeks. The treatment is a carefully planned sequence of exercises intended to help children with spastic hemiplegic cerebral palsy develop their fine motor abilities. Activities includes Sticker Sorting, Beads on Parade, Pegboard Activities, Sensory Bins, Sculpture Building, Finger Painting \& Drawing with Different Tools, Musical Instrument Play. Smartwatches that have tactile sensations and auditory indications are used strategically during certain tasks to enhance proprioception and give real-time feedback, making the rehabilitation process vibrant and interesting.
Study: NCT06269679

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBCT
Description: Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
Study: NCT05766670

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin Hydrochloride
Description: The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.

Intervention type: DRUG
Group type: OTHER
Intervention: Gentamicin
Description: The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Intramedullary Nail
Description: Standard Intramedullary Nail
Study: NCT06103565

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Decision Support Tool
Description: Clinical decision support tool to enable pharmacists to monitor adherence to guideline-directed medical therapy for patients with heart failure with reduced ejection fraction
Study: NCT06251908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rewritalize
Description: REWR is conceptualised as a hybrid between an art group and a group therapy intervention. It is structured as a progressive participatory art group program led by a conductor-tandem: the primary conductor, a professional writer with extensive teaching experience, is supplemented by a co-conductor with clinical expertise who participates in the group activities together with the other participants. The conductor-tandem secure high artistic standards while also ensuring psychological safety. A close collaboration between the two is necessary and both participate in a 30-hour preparatory course and are supervised during the course of the intervention.~The writing course consists in 15 sessions of 3 hours per session. At each session participants are introduced to literary texts that work as prompts for the writing exercises, which last 5-15 min. After each text is read out loud, the participants engage in a reflective discussion about the text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard mental health care
Description: F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard mental health care
Description: F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs.
Study: NCT06576908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperSight Imaging
Description: Subjects receive both HyperSight imaging and conventional imaging, on their first day of radiation treatment, on their second day of treatment, and on their last day of treatment.
Study: NCT02178618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deployment of Partially covered biliary self expandable metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deployment of uncovered biliary self expandable metal stent